4-((2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde | 1372195-41-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde
• 英文别名: 4-((2',6'-Dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde；4-[[3-(2,6-dimethylphenyl)phenyl]methoxy]benzaldehyde
• CAS: 1372195-41-9
• 化学式: C₂₂H₂₀O₂
• 分子量: 316.4
• InChiKey: YDJOPVSCNKHWCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-((2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde 在 sodium methylate 、 三氟乙酸 、 sodium chloride 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.5h， 生成 5-[4-[[3-(2,6-dimethylphenyl)phenyl]methoxy]phenyl]-1,1-dioxo-1,2-thiazinan-3-on
  参考文献：
  名称：

  CYCLIC AMIDE DERIVATIVE

  摘要：

  为提供一种具有GPR40激活剂作用的新化合物、该化合物的盐、盐或化合物的溶剂合物，尤其是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖或其他疾病的药剂，解决问题的方法是使用Formula (1)的化合物：(其中n为0至2；p为0至4；h为0至3；j为0至3；k为0至2；环B为芳香族或杂环芳基；X为O、S或-NR7-；J1为-CR11aR11b-或-NR11c-；J2为-CR12aR12b-或-NR12c-；R1到R12为特定基团)，该化合物的盐，或盐或化合物的溶剂合物。

  公开号：

  US20130203739A1
• 作为产物：
  描述：

  3-溴苯甲醇 在 四(三苯基膦)钯 、 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 水 、 甲苯 为溶剂， 反应 32.0h， 生成 4-((2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methoxy)benzaldehyde
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists

  摘要：

  Diabetes mellitus is a chronic metabolic disorder that affects more than 180 million people worldwide. Peroxisome proliferator activated receptors (PPARs) are a group of nuclear receptors that have been targeted by the thiazolidinedione (TZD) class of compounds for the management of type II diabetes. PPAR gamma is known to regulate adipogenesis and glucose metabolism. Another emerging target for the design of antidiabetic agents is the free fatty acid receptor 1 (FFAR1), previously known as GPR40. Agonists of this receptor were found to enhance insulin secretion in diabetic patients. It has been reported that some thiazolidinediones (TZDs) activate FFAR1 with micromolar potency. In this study, based on docking studies into the crystal structure of PPAR gamma and a homology model of FFAR1, nineteen compounds were designed, synthesized, and biologically tested for agonistic activity on both receptors. Nine compounds showed promising dual activity, with two compounds, 11a and 5b, having affinities in the low micromolar range on both targets. These molecules represent the first antidiabetic agents that could act as insulin sensitizers as well as insulin secretagogues. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.049

文献信息

• Cyclic amide derivative
  申请人：Okano Akihiro

  公开号：US09072758B2

  公开（公告）日：2015-07-07

  [Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogues and a prophylactic and/or therapeutic agent against diabetes, obesity, or the like. [Means of solving the problem] A compound of Formula (III): (where f is 0 to 2; g is 1 to 4; j is 0 to 3; k is 0 to 2; n is 0 to 2; p is 0 to 4; h is 0 to 3; q1 id 0 to 3; q2 is 0 or 1; r1 is 0 to 2 (with the proviso that q1+q2+r1 is 0 to 5); J1a is —CR11a—, N; J2 is —CR12aR12b—, —CR12c—; T is —CH2—, O, —S(O)i— (i is an integer of 0 to 2) or —NR7—; X is O, S, or —NR7—; ring A′″ is a benzene ring, a pyridine ring; ring B′ is a benzene ring, a pyridine ring, a pyrimidine ring; and R1 to R14 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

  [问题]提供一种GPR40激活剂，其活性成分为具有GPR40激动剂作用的新化合物、该化合物的盐、盐或化合物的溶剂化物等，特别是胰岛素分泌剂和预防和/或治疗糖尿病、肥胖症等的药物。[解决问题的方法] III式的化合物：（其中f为0至2；g为1至4；j为0至3；k为0至2；n为0至2；p为0至4；h为0至3；q1为0至3；q2为0或1；r1为0至2（前提是q1+q2+r1为0至5）；J1a为—CR11a—，N；J2为—CR12aR12b—，—CR12c—；T为—CH2—、O、—S（O）i—（i为0至2的整数）或—NR7—；X为O、S或—NR7—；环A'″为苯环、吡啶环；环B'为苯环、吡啶环、嘧啶环；R1至R14为特定基团）的盐或盐或化合物的溶剂化物。
• Oxadiazolidinedione Compound
  申请人：Negoro Kenji

  公开号：US20090186909A1

  公开（公告）日：2009-07-23

  [Problem] A compound which can be used as a pharmaceutical, particularly a insulin secretion promoter or a agent for preventing/treating disease in which GPR40 is concerned such as diabetes or the like, is provided. [Means for resolution] It was found that an oxadiazolidinedione compound which is characterized by the possession of a benzyl or the like substituent binding to the cyclic group via a linker at the 2-position of the oxadiazolidinedione ring, or a pharmaceutically acceptable salt thereof, has excellent GPR40 agonist action. In addition, since the oxadiazolidinedione compound of the present invention showed excellent insulin secretion promoting action and blood glucose level-lowering action, it is useful as an insulin secretion promoter or an agent for preventing/treating diabetes.

  【问题】提供一种可用作药物的化合物，特别是胰岛素分泌促进剂或用于预防/治疗涉及GPR40的疾病，如糖尿病等。 【解决方法】发现一种氧代唑烷二酮化合物，其特征在于在氧代唑烷二酮环的2位通过连接基与环上的苯甲基或类似取代基结合，或其药学上可接受的盐具有优异的GPR40激动剂作用。此外，由于本发明的氧代唑烷二酮化合物表现出良好的胰岛素分泌促进作用和降低血糖水平的作用，因此它可用作胰岛素分泌促进剂或预防/治疗糖尿病的药物。
• US7968552B2
  申请人：——

  公开号：US7968552B2

  公开（公告）日：2011-06-28
• US9040525B2
  申请人：——

  公开号：US9040525B2

  公开（公告）日：2015-05-26
• US9072758B2
  申请人：——

  公开号：US9072758B2

  公开（公告）日：2015-07-07